Catalyst Wire Dossier Catalyst Wire Dossier

E.E.S 400

ERYTHROMYCIN ETHYLSUCCINATE · Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for E.E.S 400, covering 2006-07-21 to 2015-09-01. Get the full timeline:

Most recent: FDA Approved: E.E.S 400 — Supplemental Application (Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals))

See pricing